Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 30, 2017updated 26 Nov 2018 11:09am

Ra Medical secures FDA clearance for new PAD treatment system

Ra Medical Systems, an excimer lasers and catheters developer, has secured clearance from the US Food and Drug Administration (FDA) to market its new laser radiation ablation (DABRA) system for the treatment of peripheral artery disease (PAD).

Ra Medical Systems, an excimer lasers and catheters developer, has secured clearance from the US Food and Drug Administration (FDA) to market its new laser radiation ablation (DABRA) system for the treatment of peripheral artery disease (PAD).

Designed as a less-expensive and safer solution, DABRA eliminates blockages from arteries in the limbs and is effective on all types of lesions.

In addition to altering the arteries, the new system can bypass the lesion and cross the chronic total occlusions (CTOs) with a wire.

Ra Medical Systems co-founder and chief executive officer Dean Irwin said: “DABRA’s US market clearance is the realisation of more than a decade of dedication to the pursuit of delivering a more effective, safer and less expensive way to remove blockages from arteries to save limbs and, ultimately, save lives.

"DABRA’s US market clearance is the realisation of more than a decade of dedication to the pursuit of delivering a more effective, safer and less expensive way to remove blockages from arteries to save limbs and, ultimately, save lives."

“To do so, we built Ra Medical Systems and pioneered our cost-effective, small and portable Pharos excimer laser for dermatological diseases, creating our company infrastructure and self-funding the development of DABRA.”

Expected to result in interventional procedures and better patient access, DABRA is said to require less procedural time, when compared to existing arterial blockage treatments.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The wireless system is considered to be safe as it remains in the patient’s true lumen and does not require subintimal access or perforation.

Its safety profile was confirmed in a clinical study, which demonstrated 95% positive outcome without clinically significant adverse events.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU